Lupin Limited — Q4 FY25 earnings call

Call held 15 May 2025

Management summary

Lupin reported a stellar FY25 with strong revenue and EBITDA growth, driven by robust performance in the US and India markets. Margin expansion was significant, and the company achieved a zero-debt status. While adjacency businesses are still in investment phase and loss-making, the core business shows strong momentum with a focus on complex generics and chronic therapy areas.

Highlights

  • FY25 revenue of USD 2.7 billion and EBITDA of USD 625 million, demonstrating strong growth momentum.

  • EBITDA margins expanded to 23.2% in Q4 FY25, with an adjusted core margin of 26% after accounting for adjacencies and PLI.

  • US business achieved 17% growth in FY25, driven by complex generics which now constitute 30% of US revenues.

  • India business grew 14% in FY25, with chronic share improving to 64% and a target of 69-70% by FY30.

  • Company is now zero-debt and cash surplus, with FY25 free cash flow of INR 1,330 crores.

Concerns

  • India's in-licensed product portfolio experienced de-growth of 12% in FY25 due to loss of exclusivity, impacting overall India growth.

  • Adjacency businesses (diagnostics, digital health, OTC, CDMO) are currently loss-making, impacting overall EBITDA margin by 3.5-3.7 percentage points.

  • Two manufacturing sites (Mandideep and Tarapur) are still awaiting FDA approval, though management expresses confidence in their readiness.

Key financials

  1. Revenue 2.7 Bn
  2. EBITDA 625 Mn
  3. EBITDA Margin 23.2%
  4. Gross Margin 69.2%
  5. ROCE 20%
  6. Free Cash Flow ₹1,330 Cr

What they filed

Q1 FY27: revenue up 25.6%, net profit up 27.6% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue4,106 4,208 4,486 5,709 4,068 −1%4,501 +7%5,235 +17%7,172 +26%
EBITDA1,115 1,411 1,746 2,730 1,176 +5%1,617 +15%2,282 +31%3,733 +37%
Net profit808 985 1,291 2,128 1,357 +68%717 −27%2,164 +68%2,715 +28%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • US
    925 Mn Revenue17% Growth30% Complex Generics Share
  • India
    14% Growth64% Chronic Share-12% In-license Portfolio De-growth
  • EMEA
    22% Growth55% Complex Generics Share
  • LATAM
    10% Growth
  • APAC
    5% Growth
  • ROW/GIB
    11% Growth
  • API
    3% Growth
  • Lupin Diagnostics
    44% Revenue Growth
  • Lupin Life (OTC)
    ₹150 Cr Revenue

Capital allocation

high confidence
  • Capex Capex disclosed
    • Maintenance capex and expansion in biosimilars, injectables, and other areas ₹500 Cr
    I showed only one figure which is the capital expenditure on an annual basis for 4-5 years really. And that I think average is about INR 500 to INR 700 crores. A larger chunk was for really maintenance capex and there's been some expansion in some parts especially when it comes to biosimilars, injectables and the likes.
  • Debt Net ₹0 Cr · 0.0× EBITDA
    We are a zero-debt company at this point, have strong cash flows and have considerably improved our ROCE from the 10 % level to 20%. So very pleased with the financial results of all of the efforts over the last many years.
  • M&A Lilly's insulin brand Acquisition · Closed

    Enables gaining end-to-end economics on the product and expanding footprint in India.

    You saw recently we acquired the insulin brand from Lilly, which enables us to really gain the end-to-end economics on the product.
  • M&A Medisol Acquisition · Closed

    Provided presence in France and a nice injectables portfolio.

    Medisol in France that enabled us to get into, we didn't have a presence in France until we acquired Medisol, which gave us a very nice injectables portfolio that enables us to build our internal pipeline on top of this to build a business in France.
  • M&A Southern Cross Acquisition · Closed

    Allowed to almost double business and contributed significantly to growth in the Australian market.

    And Southern Cross in Australia that allowed us to almost double our business, has been a significant contributor to growth in the Australian market and has enabled us to get to that position of 4th largest generic in the Australian market.
  • M&A Xopenex® Acquisition · Closed

    Enabled entry into the brand side of the business, particularly in respiratory.

    We have also had strategic acquisitions over the last 5 years. Xopenex® in the US enabled us to get into the brand side of the business.
  • Liquidity Liquidity disclosed Company is cash surplus with strong cash flows, reporting INR 1,330 crores in free cash flow for FY25.
    We are a zero-debt company at this point, have strong cash flows and have considerably improved our ROCE from the 10 % level to 20%. So very pleased with the financial results of all of the efforts over the last many years.

Guidance & targets

India Business Growth

  • India market growth multiple India Business Growth · many years · High confidence 1.2-1.3 times the market
    We'd like to grow 1.2, 1.3 times the market and we have done that in many years.

    — Vinita Gupta

India Sales Force Expansion

  • Number of representatives added India Sales Force Expansion · every year · High confidence 400-500 representatives
    Basically programmatically, we want to add the 400-500 representatives every year.

    — Nilesh Gupta

India New Product Launches

  • Number of NPLs India New Product Launches · next five years · High confidence 80 products
    NPLs, new product launches, is going to be a key growth driver, over 80 products in our portfolio for the next five years.

    — Nilesh Gupta

India Chronic Share

  • Percentage of sales from chronic products India Chronic Share · by FY30 · High confidence 69-70%
    If you look at the current portfolio, 64% of sales come from chronic. If you see by FY30, it'll actually move to 70%, 69% - 70%.

    — Nilesh Gupta

Lupin Life (OTC) Revenue

  • Revenue growth Lupin Life (OTC) Revenue · next three to four years · Medium confidence more than double
    Lupin Life is our OTC business, INR 150 crores, big plans to grow. The aspiration is to well more than double this in the next three to four years.

    — Nilesh Gupta

Lupin Diagnostics Profitability

  • EBITDA status Lupin Diagnostics Profitability · FY27 · High confidence EBITDA positive
    The target is to be EBITDA positive in FY27.

    — Nilesh Gupta

US Complex Generics Share

  • Percentage of US revenues US Complex Generics Share · next five years · High confidence 49%
    If you look at the next five years, that complex generics will move to 49% of revenues.

    — Nilesh Gupta

  • Percentage of US revenues US Complex Generics Share · by FY30 · High confidence 55%
    If you see the US, FY20 complex generics was 2% of the business, grew to 34% in FY25. And if you see again the next five years, will grow to 55% of the business in the US.

    — Nilesh Gupta

Europe Complex Generics Share

  • Percentage of Europe business Europe Complex Generics Share · by FY30 · High confidence two-thirds
    In Europe,, 9% was the composition of complex platforms in FY20, 55% at this point of time and growing to two-thirds of the business by FY30.

    — Nilesh Gupta

R&D Spend

  • R&D spend as % of sales R&D Spend · next year · High confidence upward of 8.5%

    From 8% today

    Therefore, the absolute numbers are set to go up. And as a percentage of sales also so it is about 8% right now. So, I believe that will be upward of 8.5% next year.

    — Ramesh Swaminathan

EBITDA Margin

  • EBITDA margin trend EBITDA Margin · next several quarters · Medium confidence continuously go up
    So, the margins would continuously go up.

    — Ramesh Swaminathan

ROCE

  • ROCE percentage ROCE · future · Medium confidence 27-28%

    From 20% today

    Today, it's a good 22%. Still a far cry from what we were about a few years ago. We were 27% - 28%. And it's a question of time we get to those levels.

    — Ramesh Swaminathan

Debt

  • Debt to EBITDA ratio Debt · future · Medium confidence around 2:1

    From 0 today

    If we are talking about EBITDA close to about INR 5,000 - 5,500 crores and you are talking about potentially the debt we can raise is about INR 10,000 - 11,000 crores. We are also kind of prioritizing in terms of where we will be putting our money in and from our perspective it is going to be in India and of course specialty. Though we would of course like to address white spaces in distribution program across say geographies like Europe. And we have also said that when it comes to adjacencies, we would restrict our overall involvement to what we envisaged at the time of drawing up the investment program for various adjacencies. Beyond that we would actually involve private equity houses or a potentially strategic of the like. So, we also said in terms of financial returns we would be expecting return of about 20% and in terms of a payback period between 4 to 6 years depending upon the project. So, some of these guardrails are already operational. And going forward we would make sure that most of the projects qualify under this.

    — Ramesh Swaminathan

What to watch in Q1 FY26

FDA approval status of Mandideep and Tarapur sites

near future
Current Awaiting FDA approval
Target FDA approval received

Why it matters

Resolution of these sites is crucial for full operational flexibility and potential new product approvals.

I am confident if the FDA was to visit the 2 pending sites, Mandideep as well as Tarapur, our sites are ready to receive them. But we don't have any pending products from the sites, so they don't have any hurry to come in and inspect these sites. But I am confident in the near future we will get those sites cleared as well.

Risks & concerns

  • FDA regulatory status of manufacturing sites

    medium

    Two sites (Mandideep and Tarapur) are still awaiting FDA approval, though no pending products from these sites.

    I'd say 11 right now because the Pune biotech facility is yet to be approved by the FDA, but have multiple manufacturing sites that are approved by the FDA, as well as other regulators that enable us to build our generic business.

    Management acknowledged

  • Profitability of adjacency businesses

    medium

    Adjacency businesses (diagnostics, digital health, OTC, CDMO) are currently loss-making, impacting overall EBITDA margin.

    And the other thing that you should certainly take into account is the fact that some of our adjacencies that we started in recent times are still making a loss.

    Management acknowledged

  • Competition and pricing pressure for key products

    medium

    Albuterol is facing pressure, and Tolvaptan will see competitors, potentially leading to share loss.

    So hopefully it is higher. We think that you know we are going to see pressure on Albuterol, we have already started seeing it. We think Tolvaptan will be a great contributor in the first half of this fiscal year. But second half we certainly expect other competitors to come in and while our first mover advantage will be there because it is a specialty drug, it is a REMS product we will expect to give up share.

    Management acknowledged

Q&A highlights

7 direct
Impact of MFN policy on drug pricing Direct
I think the MFN would definitely impact the brand side of the business much more than the generic and the focus under IRA has been on the highest value drugs. So, it is really the highest value drugs that will likely get impacted. I think that at the end of the day the value of the brand has an impact on the opportunity for generic.

Clarifies management's view that MFN primarily targets branded drugs, not generics, and expects litigation to challenge it.

Asked by Kunal Lakhan

Flexibility for US manufacturing expansion and tariffs Direct
If there is a need to manufacture essential drugs in the US, we will explore it. We are actively exploring that with the National Security Council as part of the White House right now. The government has identified 9 drugs that they believe that are essential and we go into the dialogue back and forth with them to determine how we can build the partnership between India and the US to give them the confidence that they will have reliability of supply.

Indicates willingness to expand US manufacturing if government incentives are provided, aligning with de-risking strategies.

Asked by Kunal Lakhan

Impact of Medicaid cost cuts on Indian pharma Direct
I think a big part of CMS spending is on branded drugs, so I think the first impact you would see is on branded drugs. And that's what they are trying to do with this MFN clause, to negotiate pricing on brand drugs at a level similar to Europe. I don't expect it to get to generic drugs very quickly because, generic drugs are already a pretty low spend.

Reassures that Medicaid cost cuts are unlikely to significantly impact generic drug pricing due to their already low cost.

Asked by Krishnendu Saha

Cannibalization between insulin acquisition and Semaglutide launch in India Direct
No, Semaglutide apart from diabetes because there is separate market for GLP-1s, there is a separate market for insulin, and particularly in obesity insulin has no role. So GLP-1s are going to be the one which are going to play a major role in obesity.

Clarifies that Semaglutide will not cannibalize insulin sales, as they target different market segments (GLP-1s for obesity/diabetes, insulin for diabetes).

Asked by Krishnendu Saha

Status of Mirabegron sales and litigation Direct
We continue to sell the product no change. And we have the trial in February, and believe that we have plenty of defences that, you know we have a good chance to fight at that point in time. So, we will find out in February.

Confirms continued sales of Mirabegron and confidence in legal defense against infringement.

Asked by Krishnendu Saha

Timeline and profitability of CDMO initiatives Partial
It is fully functional, I mean it is a separate entity altogether, they have a separate office, they don't even sit in the Lupin offices, so they are fully functional already. The entire business is about building a funnel, so we want to build that funnel with good number for this year as well. I think the revenues it will be nothing meaningful at this point of time, I think in the next two years it will get to a meaningful number.

Provides a timeline for when the CDMO business is expected to contribute meaningfully to revenues (within two years).

Asked by Surya Patra

Adjusted core EBITDA margin for the quarter Direct
In terms of adjacencies, this is essentially the digital business, the diagnostics, API CDMO, the bio business, all of these are still evolving. So, if we were to knock out that impact it will be about 3.5 to 3.7 percentage points. And in terms of the first part of the question, we lost out in terms of PLI - not lost out it was actually capping out because there is a limit to what we can claim for any year. So, previous quarter was higher by about INR 50 crores. This quarter that's the impact it is about 1% lower because of that and the higher impact in terms of R&D I will specify that again, the R&D spends are lot higher. If we knock out that impact, then potentially that 23.2% would have been 26%.

Clarifies the impact of loss-making adjacencies and PLI adjustments on the reported EBITDA margin, indicating a stronger core business profitability.

Asked by Surya Patra

Biosimilar strategy and late entry Direct
It has been quite an evolution. The strategy has been evolving on the biosimilars front just given the market evolution. When you look at the changes that have taken place in the US. It is really creating opportunity for older products as well for us. For example, Pegfilgrastim it's a very old product, multiple players in the marketplace. But as we have had conversations over the last year with the customer base the fact that we will come in with a new ASP that's attractive for providers makes it a very attractive opportunity.

Explains the evolving biosimilar strategy, focusing on selective products and leveraging private label models or direct market entry in the US, even for older products.

Asked by Kunal Randeria

2 min read 6 chapters

Detailed narrative

Strong FY25 Performance and Growth Drivers

Lupin reported a stellar fiscal year 2025, achieving USD 2.7 billion in revenue and USD 625 million in EBITDA. The company saw significant growth across all key markets, with North America growing 16%, US specifically 17%, India 14%, and EMEA 22%. Gross margins improved from 64% to 69% over the last five years, reaching 69.2% in Q4 FY25, while EBITDA margins expanded from 16% to 24% over the same period, hitting 23.2% in the latest quarter.

US Business Turnaround and Complex Generics Focus

The US business experienced a significant turnaround, growing 17% in FY25 to USD 925 million. Complex generics now account for 30% of US revenues and are projected to reach 49% in the next five years and 55% by FY30. Key product launches like Mirabegron, Tolvaptan, and Spiriva have been instrumental. The company holds the 3rd largest position in the US by prescriptions dispensed, with 4.9% market share.

India Business Expansion and Chronic Portfolio Shift

Lupin's India business grew 14% in FY25, despite a 12% de-growth in its in-licensed portfolio due to loss of exclusivity. The focus on chronic therapy areas has increased the chronic share from sub-60% five years ago to 64% currently, with a target of 69-70% by FY30. The sales force has expanded from 5,000 to over 10,000, and the company plans to add 400-500 representatives annually, aiming for 1.2-1.3 times market growth.

Strategic Adjacencies and Future Growth Pillars

Lupin is investing in strategic adjacencies beyond prescription medicine, including diagnostics, digital health, and OTC products. Lupin Diagnostics achieved 44% YoY revenue growth and aims to be EBITDA positive by FY27. Lupin Life (OTC) generated INR 150 crores and targets to more than double in the next 3-4 years. The company is also building a CDMO business leveraging its API capabilities, which is expected to contribute meaningfully within two years.

Capital Allocation and Financial Health

The company has achieved a zero-debt status and reported strong free cash flow of INR 1,330 crores in FY25. ROCE has improved from 10% to 20% over the last five years, with a target to reach 27-28%. Future capital allocation will prioritize India and specialty businesses, with a potential debt-to-EBITDA ratio of around 2:1 for M&A opportunities. R&D spend, currently around 8% of sales, is expected to increase to upward of 8.5% next year, focusing on complex generics and novel products.

Regulatory and Market Landscape

Lupin has made significant strides in compliance, with 3 out of 5 warning letter sites cleared. Two sites (Mandideep and Tarapur) are still awaiting FDA approval, but management is confident in their readiness. The company is actively engaging with the US government on bilateral trade negotiations to address tariffs and potential US manufacturing incentives. Management believes the MFN policy will primarily impact branded drugs, not generics, and expects litigation to challenge it.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls